Nirsevimab EMA regulatory submission accepted under accelerated assessment
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Adds five years of market exclusivity on approval
Clarithromycin tablets USP, 250 mg and 500 mg have an estimated market size of US $ 11 million for twelve months ending September 2021 according to IQVIA
The country is sixth among the most affected countries by active cases
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Ind-Ra expects revenue growth of over 12% in 2022.
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Recent Study by Columbia University finds Mylab’s CoviSelf can detect the Omicron variant successfully
Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Doxycycline Hyclate Delayed Release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
Subscribe To Our Newsletter & Stay Updated